China Pharma Holdings, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are with FY2022. Filed April 1, 2024. China Pharma is a Nevada holding company; substantially all operations are conducted in China through its subsidiary Helpson, which develops, manufactures, and sells pharmaceutical and healthcare products.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $7.01 million | $8.10 million |
| Gross loss (margin) | $0.28 million (4.0%) | $0.49 million (6.1%) |
| Operating loss | $2.75 million | $3.55 million |
| Net loss | $3.08 million | $3.97 million |
| Net loss per share, basic and diluted | $0.91 | $3.78 |
| Net cash used in operating activities | $0.70 million | $0.41 million |
| Cash and cash equivalents at year-end | $1.42 million | $2.03 million |
Cost of revenue was $7.29 million, exceeding revenue. Selling expenses fell to $0.78 million from $1.07 million; general and administrative expenses were $1.47 million versus $1.89 million; research and development expenses rose to $0.24 million from $0.19 million. Net interest expense was $0.33 million, compared with $0.42 million.
At year-end, total assets were $16.47 million and total liabilities were $9.01 million. Current assets of $6.00 million were below current liabilities of $6.82 million. Inventory was $3.73 million. Net trade receivables were $0.50 million, against gross receivables of $14.36 million and an allowance of $13.79 million; 96.4% of gross receivables were over 720 days old and fully reserved. Cash held in China is considered indefinitely reinvested and is not expected to be available for parent-company or shareholder payments.
Debt included lines of credit totaling approximately $2.44 million, with amounts due in 2024, and a convertible note with a stated principal balance of approximately $1.42 million at December 31, 2023. The note was extended to May 19, 2024; its balance-sheet carrying amount, net of discount, was $0.94 million. The company also reported $1.13 million in advances from its CEO for operations. A $1.41 million Bank of China facility is secured by the new production facility and equipment and personally guaranteed by the CEO.
Changes from FY2022
- Revenue declined $1.09 million, or about 13%, primarily because products that had not passed generic-drug consistency evaluation were ineligible for centralized procurement (CP). Anti-infection and respiratory sales fell 28% to $3.57 million, including lower Roxithromycin sales.
- Digestive-disease revenue increased 166% to $1.09 million, primarily due to Omeprazole sales. CNS and cardiovascular revenue decreased 5% to $1.62 million.
- Net loss narrowed by approximately $0.89 million, as expense reductions more than offset lower revenue. Gross loss also narrowed, but the company continued to sell below cost.
- Operating cash use increased by approximately $0.29 million, and cash declined by approximately $0.61 million. Financing cash flow was a $0.07 million source in 2023, versus $1.77 million used in 2022.
- Candesartan passed generic-drug consistency evaluation in August 2023. The company issued shares for an acquired COPD-related patent and technology in December 2023, and later disclosed a further patent acquisition in February 2024.
Outlook, risks and unusual items
- Going concern: The auditor and management disclose substantial doubt about the company’s ability to continue as a going concern, citing recurring operating losses, net current liabilities, and accumulated deficit of $39.29 million. Management cites advance-payment sales, stronger receivables collection, healthcare-product initiatives, CEO support, and potential borrowing against fixed assets; it acknowledges these plans are not assured. The auditor’s report is unqualified but highlights the going-concern uncertainty.
- No quantified guidance: The filing gives no specific revenue, earnings, margin, or cash-flow forecast. Management says existing resources are expected to fund operations for at least 12 months, while also warning financing may be needed and may not be available on acceptable terms.
- Pricing and market access: China’s centralized procurement and medical-insurance cost controls can sharply reduce drug prices. The filing cites average price reductions above 50% in national procurement rounds and says consistency evaluation is increasingly important for procurement eligibility. Helpson’s strategy emphasizes completing evaluations, product differentiation, healthcare products, distribution expansion, and potential CDMO services.
- Convertible-note and dilution risk: The investor can redeem the note in cash or convert at 82% of a recent low-volume-weighted average price, subject to the note terms. Default could trigger additional interest and penalties. The company issued shares in 2023 to settle related-party debt and in exchange for intangible assets; additional redemptions and a patent-related share issuance occurred after year-end.
- Other material risks: Dependence on China-based operations, evolving PRC regulation, currency-conversion and remittance restrictions, product and manufacturing compliance, distributor collections, competition, and potential product liability. The company reports no product-liability, business-interruption, or directors-and-officers insurance; it also identifies dependence on certain distributors and substantial aged receivables.
- Controls and corporate matters: Management found disclosure controls and internal control over financial reporting ineffective at year-end due to a material weakness involving insufficient personnel knowledgeable in U.S. GAAP. Remediation efforts include staff training and process review. The company does not expect to pay cash dividends. A 1-for-5 reverse stock split became effective March 6, 2024; share and per-share disclosures were retroactively restated.
Important facts for investors to verify
- Near-term liquidity, refinancing of 2024 obligations, the convertible note’s repayment or extension, and the status and terms of subsequent redemptions.
- Whether operating cash flow, receivables collections, and advance-payment sales improve, given the large gross receivable balance and high allowance.
- Progress on consistency evaluations and whether key products can regain procurement access without further material price reductions.
- Commercialization, regulatory approval, funding, and potential dilution associated with acquired formulas and patents.
- Implementation and effectiveness of internal-control remediation, and reconciliation of share counts and per-share data following stock splits and share issuances.